Ranbaxy merger showing sharp cons as well as pros for Sun Pharma

The merger with Ranbaxy by Sun Pharmaceuticals has given the company scale to move up the food chain in the industry but has also come at a cost to the enlarged entity, Business Today reports. The deal made Sun the world's fifth-largest generic drug maker and moved it up the corporate rankings in India but tied the company to Ranbaxy plants that have been banned by the U.S. FDA for not meeting quality standards. Legal fees, high staff costs and a one-time writedown of about $94 million hurt profitability, as did problems at one of the company's U.S. plants and declining prices in several categories, Business Today said. Report

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

North Korean hackers are accused of targeting COVID-related firms. Zai Lab poached a Genentech R&D exec. Daiichi formed a new oncology business unit.

Ad Environment Matters for Message Receptivity

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.